Growth hormone: Effects, Risks & Research

Growth hormone

Somatropin is a manufactured form of human growth hormone used for specific medical conditions.

Established medical uses

Also known as: HGH · GH · somatropin

Practical use

Applying the explained evidence

Where it fits: Somatropin is a manufactured form of human growth hormone used for specific medical conditions.
Put the information into practice: Diabetes, cancer history and certain acute illnesses are important considerations. Product-specific prescribing information and the patient’s diagnosis determine whether treatment is appropriate.
Outcome versus a marker: Separate a change in a hormone measurement or body-composition estimate from the outcome you actually care about. Look for direct measurement of function, symptoms and adverse events.
Keep this limit in view: A narrow sprint-test finding is not a general strength or endurance benefit, nor evidence of long-term safety. The study design and duration do not establish lifelong performance or body-composition effects.

MedlinePlus: somatropin

Growth hormone in recreational athletes

Overview

Somatropin replaces growth hormone and has uses in selected growth disorders and other specific conditions. A prescription indication is different from evidence supporting physique enhancement in a healthy adult.

Risks and limitations

Reported effects include joint discomfort, swelling and nerve symptoms. Severe headache with visual changes, a serious allergic reaction or significant abdominal pain requires prompt medical evaluation.

How to read this

Diabetes, cancer history and certain acute illnesses are important considerations. Product-specific prescribing information and the patient’s diagnosis determine whether treatment is appropriate.

Research explained

Growth hormone in recreational athletes

Who was studied

Randomized, blinded trial; eight weeks of treatment followed by six weeks of washout.

What was found

Sprint capacity increased by approximately 3.9% in the combined male/female GH comparison. Other measured performance outcomes did not significantly improve.

What it cannot establish

A narrow sprint-test finding is not a general strength or endurance benefit, nor evidence of long-term safety. The study design and duration do not establish lifelong performance or body-composition effects.

Read the original study

Body composition and performance are different outcomes

A change in a body-composition measurement does not identify how much useful contractile tissue was gained. Evaluate an actual strength, endurance or function test alongside the measurement. In the recreational-athlete trial, improvement was specific to sprint capacity; it did not apply equally to the other performance measures.

Supporting source

GH is not the same thing as IGF-1

Growth hormone and IGF-1 belong to a related endocrine system but are different molecules. Somatropin is GH; mecasermin is recombinant IGF-1. A medicine that stimulates GH release is a third type of intervention. Results from one should not be transferred to another simply because all appear in a “growth” category.

Formulations and half-life

Somatropin and longer-acting growth-hormone medicines are not interchangeable by name. Pharmacokinetic measurements depend on the actual formulation and route. A hormone pulse, a blood concentration and a downstream IGF-1 response operate on different time scales; this article does not infer an administration schedule from them.

Common questions

Does medical use prove that it is useful for a healthy lifter?

No. Replacing a documented deficiency and trying to enhance an otherwise healthy adult are different clinical questions. Look for trials in the relevant population and read the outcome that was actually measured.